Keeping Track: Longer US FDA Reviews For Tislelizumab, Toripalimab, Olipudase; Perrigo Wants OC To Go OTC

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Keeping Track Feature image

The dog days of summer may have come to early to the US FDA, which last approved a novel agent more than a month ago.

COVID-19 is, again, a cause of delays. BeiGene, Ltd./Novartis AG’s immuno-oncologic tislelizumab became the latest casualty of the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers